At present, the combinations of the BRAF inhibitors dabrafenib (Dabra) and vemurafenib (Vemu) with the MEK inhibitors, Trame and Cobi, respectively, have become a new standard of care for the treatment of BRAF-mutant metastatic melanoma due to their improved efficacy and reduced toxicity as compared to BRAF inhibitors alone [11,12]. This evidence concerns the gene MAP2K7 and metastatic melanoma.